Atrium Therapeutics Inc.
RNA | NASDAQ
$8.41
+$0.14 (+1.69%)
Nov 2, 2026, 9:53 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 |
|---|---|---|---|
Net Income | -20.19M | -16.63M | -29.14M |
Depreciation & Amortization | 343K | 151K | 122K |
Stock-Based Compensation | n/a | n/a | 3.55M |
Other Working Capital | 11.81M | -9.12M | 1.95M |
Other Non-Cash Items | 1.4M | 13.05M | 416K |
Deferred Income Tax | n/a | n/a | 34K |
Change in Working Capital | 14.52M | -27.72M | 5.76M |
Operating Cash Flow | -3.93M | -31.14M | -19.25M |
Capital Expenditures | -36K | -2.1M | -879K |
Cash Acquisitions | n/a | n/a | n/a |
Purchase of Investments | -191.55M | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a |
Investing Cash Flow | -191.59M | -2.1M | -879K |
Debt Repayment | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 301.51M | 20.13M |
Financial Cash Flow | n/a | 301.51M | 20.13M |
Net Cash Flow | -195.2M | 267.85M | n/a |
Free Cash Flow | -3.96M | -33.24M | -20.13M |
Adj. Free Cash Flow | -3.96M | -33.24M | -23.68M |
Maintenance CapEx | -36K | -151K | -879K |
Growth CapEx | n/a | -1.95M | n/a |
Owner Earnings | -3.96M | -31.29M | -20.13M |
Add to Watchlist
Select watchlists to add or remove RNA